Antibiotics hold 64.0% in 2026, while ventilator-associated pneumonia accounts for 56.0% and injectable therapies 72.0%. Resistant pathogens sustain targeted treatment across hospital formularies, while stewardship rules restrict broad-spectrum exposure worldwide.
Hospital Acquired Pneumonia Market Analysis By Distribution ChannelHospital Acquired Pneumonia Market Analysis By End UserHospital Acquired Pneumonia Market Analysis By Infection TypeHospital Acquired Pneumonia Market Analysis By Route Of AdministrationHospital Acquired Pneumonia Market Opportunity Matrix Growth Vs ValueHospital Acquired Pneumonia Market Breakdown By Drug Class, Infection Type, And Region